Share-based Payment Arrangement, Expense of Gossamer Bio, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Gossamer Bio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Gossamer Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,666,000, a 45% decline year-over-year.
  • Gossamer Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,622,000, a 55% decline year-over-year.
  • Gossamer Bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $20,619,000, a 28% decline from 2023.
  • Gossamer Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $28,518,000, a 33% decline from 2022.
  • Gossamer Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $42,553,000, a 33% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Gossamer Bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,622,000 $2,666,000 -$2,176,000 -45% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $14,798,000 $2,586,000 -$2,415,000 -48% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $17,213,000 $2,405,000 -$3,406,000 -59% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $20,619,000 $4,965,000 -$7,194,000 -59% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $27,813,000 $4,842,000 -$1,320,000 -21% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $29,133,000 $5,001,000 -$3,196,000 -39% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $32,329,000 $5,811,000 +$3,811,000 +191% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $28,518,000 $12,159,000 +$710,000 +6.2% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $27,808,000 $6,162,000 -$3,960,000 -39% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $31,768,000 $8,197,000 -$1,802,000 -18% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $2,000,000 -$8,983,000 -82% 05 May 2023 10-K 13 Mar 2025 2024 FY
Q1 2023 $33,570,000 $8,127,000 -$2,856,000 -26% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $42,553,000 $11,449,000 +$3,790,000 +49% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025 2024 FY
Q3 2022 $38,763,000 $10,122,000 +$2,535,000 +33% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $36,228,000 $9,999,000 +$1,945,000 +24% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $34,283,000 $10,983,000 +$2,275,000 +26% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $32,008,000 $7,659,000 -$5,022,000 -40% 01 Oct 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
Q3 2021 $37,030,000 $7,587,000 -$1,336,000 -15% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $38,366,000 $8,054,000 -$846,000 -9.5% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $39,212,000 $8,708,000 +$464,000 +5.6% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $38,748,000 $12,681,000 +$5,819,000 +85% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2023 2022 FY
Q3 2020 $32,929,000 $8,923,000 +$3,195,000 +56% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $29,734,000 $8,900,000 +$3,760,000 +73% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $25,974,000 $8,244,000 +$5,155,000 +167% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $20,819,000 $6,862,000 -$3,937,000 -36% 01 Oct 2019 31 Dec 2019 10-K 03 Mar 2022 2021 FY
Q3 2019 $24,756,000 $5,728,000 -$12,441,000 -68% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020 2020 Q3
Q2 2019 $37,197,000 $5,140,000 +$3,766,000 +274% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $33,431,000 $3,089,000 +$2,484,000 +411% 01 Jan 2019 31 Mar 2019 10-Q 12 May 2020 2020 Q1
Q4 2018 $30,947,000 $10,799,000 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
Q3 2018 $18,169,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $1,374,000 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $605,000 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1

Gossamer Bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $20,619,000 -$7,899,000 -28% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025 2024 FY
2023 $28,518,000 -$14,035,000 -33% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $42,553,000 +$10,545,000 +33% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025 2024 FY
2021 $32,008,000 -$6,740,000 -17% 01 Jan 2021 31 Dec 2021 10-K 05 Mar 2024 2023 FY
2020 $38,748,000 +$17,929,000 +86% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2023 2022 FY
2019 $20,819,000 -$10,128,000 -33% 01 Jan 2019 31 Dec 2019 10-K 03 Mar 2022 2021 FY
2018 $30,947,000 +$30,915,000 +96609% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $32,000 01 Jan 2017 31 Dec 2017 10-K 24 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.